Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Determinants of discontinuation of ropinirole or pramipexole in Parkinson's disease
NL-OMON31064Not yet recruiting
- Sponsor
- Medisch Spectrum Twente
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ropinirole and pramipexole in Parkinson's disease (PD) (2 cohorts), sponsored by Medisch Spectrum Twente. Primary endpoints: Combined discontinuation of ropinirole or pramipexole treatment and DRD3 polymorphism. Planned start Aug 2007; status: not yet recruiting.
02
Drugs
ropinirolepramipexole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON31064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31064.